The global wound-care market is one of the largest underserved opportunities in healthcare — driven by megatrends that aren’t slowing down. ZegeneX is uniquely positioned to lead its next chapter.
The advanced wound-care market was valued at ~$12.5B in 2023 and is projected to exceed $25B by 2032, growing at a CAGR of 6.2% — driven by the global rise in diabetes, obesity and aging populations.
2025 global wound-care market
DFU TAM alone (ZegeneX initial focus)
A decade of compounding tailwinds — diabetes, obesity, aging.
Zegen-X5 is designed as a single therapeutic platform that can serve the largest and fastest-growing wound-care segments — sequenced for maximum capital efficiency.
~3M US patients · primary initial indication · target of first IND filing.
Highly recurrent · significant quality-of-life burden · natural Phase II expansion.
Predominantly hospital and long-term care · current SOC inadequate.
Military and emergency-care interest in shelf-stable advanced therapeutics.
Emerging opportunity — cold-chain-free product unlocks developing markets entirely.
The wound-care category hasn’t seen a category-defining innovation in decades. The world has.
537M adults with diabetes globally, projected to hit 783M by 2045. Every diabetes diagnosis is a future wound-risk patient.
Skin integrity declines with age. By 2050, 1 in 6 people globally will be over 65 — driving venous, pressure and surgical wound volume.
No truly transformative wound-care therapeutic has launched in over a decade. Standard of care is still moist dressings and growth-factor biologics with cold-chain handcuffs.
No currently approved or late-stage pipeline product combines a novel small-molecule MOA with thermostability and scalable manufacturing.
| Capability | Established Wound Care | ZegeneX |
|---|---|---|
| Novel MOA | Limited / known pathways | First-in-class upstream regulator |
| Shelf stable | Cold-chain required | 25°C / 24+ months |
| Manufacturing | Biologic complexity | Small-molecule scalability |
| Cost of Goods | High | Order-of-magnitude lower projected COGS |
| Global deployability | High-resource only | Universal — any setting, any climate |
Including segment-by-segment TAM, projected market share, COGS modeling, and global expansion path — available to qualified partners under NDA.
A preclinical-stage biopharmaceutical company developing first-in-class, shelf-stable wound healing therapeutics — making advanced care accessible everywhere.
